fashion -WSS

fashion

author：comprehensive 2025-10-01 15:39:28 - browse：6

Alnylam headquarters — Kristoffer Tripplaar/Sipa USA/AP

Alnylam Pharmaceuticals said Thursday that sales of its treatments for rare diseases grew 43% in the second quarter compared to the year-ago period, as the biotech prepares for a key meeting with the Food and Drug Administration in September.

Net product sales in the quarter were $306 million, led by Amvuttra, the company’s RNAi treatment for hereditary ATTR, with sales of $132 million, exceeding Wall Street forecasts. Sales of Onpattro, its older medicine for hereditary ATTR, were $91 million, slightly less than expectations.

The FDA has scheduled a meeting of outside experts on Sept. 13 to discuss the company’s application to expand the indication for Onpattro to include ATTR-CM, a related condition that affects the heart. The FDA decision is due by Oct. 8. An expansion would open a much larger market for the drug than its current approval, which largely targets nerve-related damage.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Anesthesiologist group: stop taking Ozempic before surgery
Next article： Texas Medical Board asked to define abortion emergency exception

hotspot

WSS

Female surgeons have lower rates of long

European regulators consider appeal over Amylyx ALS drug

Bernie Sanders bashes nonprofit hospitals over their tax breaks

STAT Readout Newsletter: Today in biotech, life science news

Top private equity targets in 2023: cardiology, clinical trials, lasers

How clinical AI models' predictive power can degrade over time

focus

fashion

entertainment

Apple is now the first public company to be valued at $3 trillion

Peter Marks talks Operation Warp Speed for Rare Diseases

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Adopting new red light myopia treatments may be short

23andMe had bad news about my health. I wish a person had delivered it

A fraught question for the kids of Alzheimer’s: Is it coming for us?

United colonoscopy coverage change 'may cost lives,' doctors say

UnitedHealth’s Q3 profit jumps as medical costs rise more slowly

23andMe had bad news about my health. I wish a person had delivered it

How clinical AI models' predictive power can degrade over time

focus

Cancer cells are shown to suck energy source from immune cells

{$content}

Readout LOUD podcast: Merger Mondays, Ozempic panic

Padmanee Sharma of MD Anderson at center of lawsuit over credit

A revolution in caring for preterm infants

AstraZeneca stays mum on Medicare drug pricing negotiations

hotspot

knowledge

hotspot

hotspot